Latest News

Kyle Marden, MD, sports neurologist and medical director of the Concussion and Sports Neurology Program at Northwestern Medicine, discusses emerging developments in concussion diagnosis and management, ongoing challenges in the field, and the future of individualized care.

A narrative review highlighted the limited pediatric-specific evidence supporting headache treatment after stroke and in cerebrovascular disorders, emphasizing consideration of vascular pathophysiology, cerebral perfusion, and collateral flow when selecting therapies.

David Stamler, MD, Chief Executive Officer of Alterity Therapeutics, discusses the FDA's alignment on the pivotal Phase 3 program for ATH434 in multiple system atrophy and what a successful trial could mean for a disease with no approved disease-modifying therapies.

Teva Pharmaceuticals' ecopipam receives priority review by the FDA, supported by studies showing sustained tic control among pediatric patients with Tourette syndrome.

The FDA granted Fast Track designation to Acadia Pharmaceuticals’ investigational remlifanserin for hallucinations and delusions associated with Alzheimer disease psychosis.

The cerebrovascular neurosurgeon at University Medical Center New Orleans discussed performing the first THUNDERBOLT stroke thrombectomy in the United States and what computer-assisted vacuum thrombectomy offers over traditional aspiration.

Alexandra Bonner, MD, a pediatric neuromuscular neurologist at Cleveland Clinic, discussed why real-time communication between specialists is the hardest part of multidisciplinary care for patients with spinal muscular atrophy.

Oak Hill Bio announced dosing of the first participant in BEACON, a pivotal phase 3 trial evaluating rugonersen, an antisense oligonucleotide originally developed by Roche, for Angelman syndrome.

Alexandra Bonner, MD, a pediatric neuromuscular neurologist at Cleveland Clinic, discussed which specialties are essential to a spinal muscular atrophy care team and why anticipating future needs has become central to the work.

Stacey Tarrant, RD, LDN, discusses how earlier treatment alongside disease-modifying therapies have changed nutritional priorities in spinal muscular atrophy, including the need to optimize growth, strength, function, and body composition.

The new data from ALKIVIA marks the first phase 3 study to show statistically significant, clinically meaningful improvement in immune-mediated necrotizing myopathy, a subtype with no approved therapy.

A phase 3 trial found that solriamfetol significantly improved wakefulness and reduced excessive daytime sleepiness in Chinese patients with obstructive sleep apnea, with a safety profile consistent with prior studies conducted in Western populations.

W. Bryan Burnette, MD, chief of neurology at Nemours Children’s Health in Jacksonville, Florida, discussed why access to adult subspecialty care has become one of the largest remaining challenges in spinal muscular atrophy.